These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36475702)

  • 1. Heparin Does Not Regulate Circulating Human PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) in a General Population-Brief Report.
    Xia VQ; Ong CM; Zier LS; MacGregor JS; Wu AHB; Chorba JS
    Arterioscler Thromb Vasc Biol; 2023 Feb; 43(2):352-358. PubMed ID: 36475702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.
    Ason B; van der Hoorn JW; Chan J; Lee E; Pieterman EJ; Nguyen KK; Di M; Shetterly S; Tang J; Yeh WC; Schwarz M; Jukema JW; Scott R; Wasserman SM; Princen HM; Jackson S
    J Lipid Res; 2014 Nov; 55(11):2370-9. PubMed ID: 25258384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-associated heparin-like molecules modulate the ability of LDL to regulate PCSK9 uptake.
    Galvan AM; Chorba JS
    J Lipid Res; 2019 Jan; 60(1):71-84. PubMed ID: 30463987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
    Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
    Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.
    Starr AE; Lemieux V; Noad J; Moore JI; Dewpura T; Raymond A; Chrétien M; Figeys D; Mayne J
    FEBS J; 2015 Jul; 282(14):2682-96. PubMed ID: 25913303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
    Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.
    Duan Y; Chen Y; Hu W; Li X; Yang X; Zhou X; Yin Z; Kong D; Yao Z; Hajjar DP; Liu L; Liu Q; Han J
    J Biol Chem; 2012 Jul; 287(28):23667-77. PubMed ID: 22593575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).
    Canuel M; Sun X; Asselin MC; Paramithiotis E; Prat A; Seidah NG
    PLoS One; 2013; 8(5):e64145. PubMed ID: 23675525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteinuria converts hepatic heparan sulfate to an effective proprotein convertase subtilisin kexin type 9 enzyme binding partner.
    Shrestha P; Yazdani S; Vivès RR; El Masri R; Dam W; van de Sluis B; van den Born J
    Kidney Int; 2021 Jun; 99(6):1369-1381. PubMed ID: 33609572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo.
    Schmidt RJ; Beyer TP; Bensch WR; Qian YW; Lin A; Kowala M; Alborn WE; Konrad RJ; Cao G
    Biochem Biophys Res Commun; 2008 Jun; 370(4):634-40. PubMed ID: 18406350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.
    Ferri N; Tibolla G; Pirillo A; Cipollone F; Mezzetti A; Pacia S; Corsini A; Catapano AL
    Atherosclerosis; 2012 Feb; 220(2):381-6. PubMed ID: 22176652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression.
    Miranda MX; van Tits LJ; Lohmann C; Arsiwala T; Winnik S; Tailleux A; Stein S; Gomes AP; Suri V; Ellis JL; Lutz TA; Hottiger MO; Sinclair DA; Auwerx J; Schoonjans K; Staels B; Lüscher TF; Matter CM
    Eur Heart J; 2015 Jan; 36(1):51-9. PubMed ID: 24603306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels.
    Lipari MT; Li W; Moran P; Kong-Beltran M; Sai T; Lai J; Lin SJ; Kolumam G; Zavala-Solorio J; Izrael-Tomasevic A; Arnott D; Wang J; Peterson AS; Kirchhofer D
    J Biol Chem; 2012 Dec; 287(52):43482-91. PubMed ID: 23135270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor.
    Romagnuolo R; Scipione CA; Boffa MB; Marcovina SM; Seidah NG; Koschinsky ML
    J Biol Chem; 2015 May; 290(18):11649-62. PubMed ID: 25778403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects.
    Tavori H; Rashid S; Fazio S
    Atherosclerosis; 2015 Feb; 238(2):264-70. PubMed ID: 25544176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.
    Rashid S; Tavori H; Brown PE; Linton MF; He J; Giunzioni I; Fazio S
    Circulation; 2014 Jul; 130(5):431-41. PubMed ID: 25070550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other.
    Butkinaree C; Canuel M; Essalmani R; Poirier S; Benjannet S; Asselin MC; Roubtsova A; Hamelin J; Marcinkiewicz J; Chamberland A; Guillemot J; Mayer G; Sisodia SS; Jacob Y; Prat A; Seidah NG
    J Biol Chem; 2015 Jul; 290(30):18609-20. PubMed ID: 26085104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
    Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG
    J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.